Profile data is unavailable for this security.
About the company
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
- Revenue in AUD (TTM)191.71k
- Net income in AUD-338.68m
- Incorporated1984
- Employees5.00
- LocationOpthea LtdSuite 0403Level 4, 650 Chapel Street, South YarraMELBOURNE 3141AustraliaAUS
- Phone+61 39826-0399
- Fax+61 39824-0083
- Websitehttps://opthea.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cogstate Ltd | 66.78m | 8.38m | 171.02m | 61.00 | 20.41 | 2.69 | 13.58 | 2.56 | 0.0485 | 0.0485 | 0.3858 | 0.3685 | 0.7762 | -- | 4.96 | -- | 9.74 | 8.45 | 12.51 | 12.30 | 55.96 | 53.13 | 12.55 | 10.75 | -- | -- | 0.0162 | 0.00 | 7.36 | 14.72 | 52.75 | -- | -5.00 | -- |
| Dimerix Ltd | 583.48k | -17.08m | 181.30m | 0.00 | -- | 9.83 | -- | 310.71 | -0.0373 | -0.0373 | 0.0013 | 0.0331 | 0.0234 | -- | 0.0612 | -- | -68.53 | -71.97 | -98.37 | -113.16 | -- | -- | -2,926.42 | -8,332.83 | -- | -- | 0.0082 | -- | 1,485.97 | 100.27 | -23.71 | -- | 17.99 | -- |
| Arovella Therapeutics Ltd | 155.73k | -8.75m | 190.12m | 14.00 | -- | 16.84 | -- | 1,220.86 | -0.0093 | -0.0093 | 0.0002 | 0.0107 | 0.0166 | -- | 30.42 | -- | -93.26 | -78.61 | -116.36 | -96.29 | 100.00 | 51.81 | -5,616.16 | -2,126.97 | -- | -1,012.45 | 0.00 | -- | -64.27 | -34.07 | 14.10 | -- | -37.76 | -- |
| Race Oncology Ltd | 832.58k | -13.82m | 243.78m | -- | -- | 13.30 | -- | 292.80 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Imugene Ltd | 0.00 | -149.68m | 275.22m | 0.00 | -- | 2.29 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Immutep Ltd | 119.62k | -42.72m | 414.55m | 19.00 | -- | 2.20 | -- | 3,465.57 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
| Opthea Ltd | 191.71k | -338.68m | 769.43m | 5.00 | -- | -- | -- | 4,013.50 | -0.5313 | -0.5313 | 0.0003 | -0.1068 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
| Mesoblast Ltd | 9.08m | -135.25m | 1.70bn | 73.00 | -- | 2.29 | -- | 186.82 | -0.1347 | -0.1347 | 0.0092 | 0.6473 | 0.0088 | -- | 3.21 | 124,326.00 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -42.32m | 1.91bn | -- | -- | 12.72 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 20 Aug 2024 | 289.74m | 23.54% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 42.86m | 3.48% |
| Vanguard Investments Australia Ltd.as of 30 Sep 2024 | 17.89m | 1.45% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 17.45m | 1.42% |
| Baker Bros. Advisors LPas of 20 Aug 2024 | 9.65m | 0.78% |
| Pengana Capital Ltd.as of 28 Jun 2024 | 5.11m | 0.42% |
| Pictet Asset Management SAas of 30 Jun 2024 | 2.59m | 0.21% |
| Charles Schwab Investment Management, Inc.as of 07 Nov 2024 | 2.35m | 0.19% |
| Vanguard Fiduciary Trust Co.as of 31 Aug 2024 | 1.16m | 0.10% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2024 | 1.05m | 0.09% |
